Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) announced that it has entered into a definitive agreement with AstraZeneca to acquire Myalept™ (metreleptin for injection), an orphan product that is indicated to treat complications of leptin deficiency in patients with generalized lipodystrophy. Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) belongs to Healthcare sector. Its net profit margin is -34.50% and weekly performance is -35.75%. On last trading day company shares ended up $21.98. Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) distance from 50-day simple moving average (SMA50) is -29.92%. Dick Costolo was at a crossroads. In May, Twitter Inc (NYSE:TWTR)’s stock had sunk to a new low as investors worried the company’s growth was stunted. Over the next few weeks, the 51-year-old chief executive summoned managers to a series of meetings. In a conference room, he drew three circles on a whiteboard. “This is how the company should be described going forward,” he said, referring to what he called “geometrically eccentric circles.” Twitter Inc (NYSE:TWTR) shares advanced 1.16% in last trading session and ended the day at $40.84. TWTR Gross Margin is 63.80% and its return on assets is -24.50%. Twitter Inc (NYSE:TWTR) quarterly performance is -5.31%. On Nov. 3, Mid-Con Energy Partners, LP (NASDAQ:MCEP) announces operating and financial results for the third quarter ended September 30, 2014. Production averaged 3,098 Boe/d, an increase of 13.7% sequentially and 22.8% year-over-year. September 2014 production, reflecting full contributions from our recently closed acquisitions, averaged 3,348 Boe/d. On 06 November, Mid-Con Energy Partners, LP (NASDAQ:MCEP) shares advanced 2.16% and was closed at $17.50. MCEP EPS growth in last 5 year was -15.39%. Mid-Con Energy Partners, LP (NASDAQ:MCEP) year to date (YTD) performance is -15.82%. Waddell & Reed Financial (NYSE:WDR)‘s stock had its “market perform” rating reissued by investment analysts at Keefe, Bruyette & Woods in a note issued to investors on Wednesday. They currently have a $52.00 price target on the stock, down from their previous price target of $57.00. Waddell & Reed Financial, Inc. (NYSE:WDR) ended the last trading day at $48.06. Company weekly volatility is calculated as 2.18% and price to cash ratio as 5.57. Waddell & Reed Financial, Inc. (NYSE:WDR) showed a weekly performance of 1.76%. On Oct. 30, ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) announced financial results for the third quarter ended September 30, 2014, and provided an update on the company's product development activities. Net loss for the third quarter of 2014 was $6.1 million, or $(0.06) per share, compared to a net loss of $16.7 million, or $(0.20) per share, for the third quarter of 2013. Included in the loss for the third quarter of 2014 was a non-cash gain of $5.8 million compared to a non-cash loss of $7.4 million for the third quarter of 2013. ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) shares advanced 1.61% in last trading session and ended the day at $3.15. ZIOP return on assets is -74.40%. ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) quarterly performance is -3.08%.
Discover Hidden Gems
Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.
